The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma
- PMID: 28958483
- DOI: 10.1016/j.hpb.2017.08.025
The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma
Abstract
Background: Although several classifications of perihilar cholangiocarcinoma (PHC) include vascular involvement, its prognostic value has not been investigated. Our aim was to assess the prognostic value of unilateral and main/bilateral involvement of the portal vein (PV) and hepatic artery (HA) on imaging in patients with PHC.
Methods: All patients with PHC between 2002 and 2014 were included regardless of stage or management. Vascular involvement was defined as apparent tumor contact of at least 180° to the PV or HA on imaging. Kaplan-Meier method with log-rank test was used to compare overall survival (OS) between groups. Cox regression was used for multivariable analysis.
Results: In total, 674 patients were included with a median OS of 12.2 (95% CI 10.6-13.7) months. Patients with unilateral PV involvement had a median OS of 13.3 (11.0-15.7) months, compared with 14.7 (11.7-17.6) in patients without PV involvement (p = 0.12). Patients with main/bilateral PV involvement had an inferior median OS of 8.0 (5.4-10.7, p < 0.001) months. Median OS for patients with unilateral HA involvement was 10.6 (9.3-12.0) months compared with 16.9 (13.2-20.5) in patients without HA involvement (p < 0.001). Patients with main/bilateral HA involvement had an inferior median OS of 6.9 (3.3-10.5, p < 0.001). Independent poor prognostic factors included unilateral and main/bilateral HA involvement, but not PV involvement.
Conclusion: Both unilateral and main HA involvement are independent poor prognostic factors for OS in patients presenting with PHC, whereas PV involvement is not.
Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Prognostic impact of the site of portal vein invasion in patients with surgically resected perihilar cholangiocarcinoma.Surgery. 2016 Jun;159(6):1511-1519. doi: 10.1016/j.surg.2016.01.012. Epub 2016 Mar 3. Surgery. 2016. PMID: 26948498
-
Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol.Transpl Int. 2015 Dec;28(12):1383-91. doi: 10.1111/tri.12640. Epub 2015 Aug 6. Transpl Int. 2015. PMID: 26183487
-
Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.Oncotarget. 2016 Jun 14;7(24):37319-37330. doi: 10.18632/oncotarget.9104. Oncotarget. 2016. PMID: 27144432 Free PMC article.
-
Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles.Int J Surg. 2020 Oct;82S:77-81. doi: 10.1016/j.ijsu.2020.04.067. Epub 2020 May 4. Int J Surg. 2020. PMID: 32380231 Review.
-
Effects of portal vein resection and hepatic artery resection on long-term survival in Klatskin tumor: a meta-analysis.World J Surg Oncol. 2022 Jul 12;20(1):230. doi: 10.1186/s12957-022-02692-1. World J Surg Oncol. 2022. PMID: 35821140 Free PMC article. Review.
Cited by
-
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.Clin Transl Med. 2024 Jun;14(6):e1723. doi: 10.1002/ctm2.1723. Clin Transl Med. 2024. PMID: 38877653 Free PMC article.
-
Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma.J Gastrointest Surg. 2020 Jul;24(7):1612-1618. doi: 10.1007/s11605-019-04127-x. Epub 2019 Feb 12. J Gastrointest Surg. 2020. PMID: 30756314 Free PMC article.
-
A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning.Front Oncol. 2021 Sep 7;11:687904. doi: 10.3389/fonc.2021.687904. eCollection 2021. Front Oncol. 2021. PMID: 34557406 Free PMC article.
-
Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing.Acta Pharm Sin B. 2024 Sep;14(9):3931-3948. doi: 10.1016/j.apsb.2024.06.028. Epub 2024 Jun 29. Acta Pharm Sin B. 2024. PMID: 39309509 Free PMC article.
-
Advances in the management of cholangiocarcinoma.World J Hepatol. 2021 Sep 27;13(9):1003-1018. doi: 10.4254/wjh.v13.i9.1003. World J Hepatol. 2021. PMID: 34630871 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical